Web Results

OSI Pharmaceuticals - Wikipedia

en.wikipedia.org/wiki/OSI_Pharmaceuticals

OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United ...

OSI Pharma, Long Island Biotech Bellwether, Shut Down by Astellas ...

www.xconomy.com/new-york/2013/05/14/osi-pharma-long-island-biotech-bellwether-shut-down-by-astellas/

May 14, 2013 ... OSI Pharmaceuticals became the home-grown beacon of Long Island, NY's biotech scene behind the lung cancer drug erlotinib (Tarceva), ...

Astellas Pharma US, Inc. | R&D

www.astellas.us/therapeutic/rnd/

Agensys, Inc., a subsidiary of Astellas Pharma Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers.

Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. - May 16 ...

newsroom.astellas.us/news-releases?item=98419

May 16, 2010 ... TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI ...

Astellas buys OSI Pharma for $4 billion in cancer push | Reuters

www.reuters.com/article/us-osi-astellas-idUSTRE64G06J20100517

May 17, 2010 ... Astellas Pharma (4503.T), Japan's No. 2 drugmaker, agreed to buy U.S. biotech OSI Pharmaceuticals OSIP.O for $4 billion in cash in a ...

Genentech: Press Releases | OSI Pharmaceuticals and Genentech ...

www.gene.com/media/press-releases/7527/2004-06-16/osi-pharmaceuticals-and-genentech-enter-

Jun 16, 2004 ... OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing Agreements for Tarceva. Melville, N.Y. and South San ...

UPDATE: Genentech, OSI shell out $67M to settle cancer-drug ...

www.fiercepharma.com/pharma/genentech-osi-shell-out-67m-to-settle-cancer-drug-marketing-claims-doj

Jun 7, 2016 ... In the first False Claims Act settlement that turns on cancer-drug survival data, Roche's Genentech unit and OSI Pharmaceuticals agreed to pay ...

OSI Pharmaceuticals LLC :: Scrip

scrip.pharmamedtechbi.com/companies/_id240

Roche and OSI Pharmaceuticals to pay $67m to resolve claims they misrepresented Tarceva effectiveness, diverting patients from first-line treatments and ...

OSI Pharmaceuticals Acquires Oncology Assets from Gilead Sciences

www.gilead.com/news/press-releases/2001/11/osi-pharmaceuticals-acquires-oncology-assets-from-gilead-sciences

OSI Pharmaceuticals (Nasdaq: OSIP) and Gilead Sciences (Nasdaq: GILD) today announced that they have signed an agreement, valued at up to $200 million ...

OSI Pharmaceuticals Inc. - Company Profile - BioCentury

www.biocentury.com/companies/osi_pharmaceuticals_inc

OSI's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry analysis.